[Modification of the expressivity of blood group antigens in urothelial bladder tumors. Prognostic value].
On the basis of 30 bladder tumours treated neither by radiotherapy nor chemotherapy, the authors undertook a study of changes in the expressivity of blood groups A and B in cases of urothelial bladder tumours. The study was carried out by indirect immunofluorescence by contact between the bladder tumour and immunoglobulins (human IgG anti-A and anti-B antibodies) and a polyvalent anti-immunoglobulin coupled with fluorescein. The conventional microscopy of these tumours uses a classification based upon that of the WHO (4 classes: I, II, III, IV) and 4 stages (0, A, B, C). The authors distinguish four types on the basis of the degree of the presence on tumour cell membranes of blood group antigens. Their findings were as follows: - the study of BGA in the epithelium near to the tumour is as important as the study of the tumour itself; - class II, stage 0 papillomatous bladder tumours retain BGA as well as in the surrounding urothelium; - carcinomatous tumours (class IV) lose in great part (type C) or completely (type D) their BGA. Tendency to recurrence or the immediate gravity of the tumour is all the greater when the expressivity of BGA is less in the surrounding epithelium; - in intermediate bladder tumours (class III), recurrences seem all the less frequent when the expressivity of BGA in the tumour and surface urothelium is better. Convinced as to the importance of this immunological study, the authors feel that it would be appropriate to continue these studies and extend labelling to H antigen and carcino-embryonic antigenic.
D000017:ABO Blood-Group System / Q000276:immunology*; D000368:Aged; D004848:Epithelium / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology
D000017:ABO Blood-Group System
Modification de l'expressivité des antigènes des groupes sanguins (A.G.S.) dans les tumeurs urothéliales de la vessie. Valeur pronostique.